(NASDAQ: ARGX) Argenx Se's forecast annual revenue growth rate of 980.58% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 56.38%, and it is also forecast to beat the US market's average forecast revenue growth rate of 9.68%.
Argenx Se's revenue in 2025 is $4,726,086.On average, 11 Wall Street analysts forecast ARGX's revenue for 2025 to be $224,795,793,589, with the lowest ARGX revenue forecast at $209,509,855,832, and the highest ARGX revenue forecast at $239,951,095,289. On average, 11 Wall Street analysts forecast ARGX's revenue for 2026 to be $291,147,062,438, with the lowest ARGX revenue forecast at $236,736,233,054, and the highest ARGX revenue forecast at $338,504,152,324.
In 2027, ARGX is forecast to generate $363,504,369,603 in revenue, with the lowest revenue forecast at $326,158,741,080 and the highest revenue forecast at $432,264,385,070.